As of 2025-07-08, the EV/EBITDA ratio of Nabriva Therapeutics PLC (NBRV) is -0.07. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NBRV's latest enterprise value is 3.29 mil USD. NBRV's TTM EBITDA according to its financial statements is -50.39 mil USD. Dividing these 2 quantities gives us the above NBRV EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.4x - 6.9x | 6.2x |
| Forward P/E multiples | 6.7x - 10.3x | 8.5x |
| Fair Price | (105.05) - (108.20) | (114.89) |
| Upside | -7498.1% - -7719.8% | -8190.8% |
| Date | EV/EBITDA |